🔗 Share this article

As America undertakes historic revisions to its vaccination guidelines, one figure appears in a surprising turn: Høeg, a Danish American sports physician and public health researcher who rose to prominence by questioning Covid vaccinations in the global health crisis and has focused upon potential deaths after COVID-19 immunization in her short time at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Immunization Schedule

Health officials planned to announce radical revisions to the pediatric immunization program recently, bringing the US with the Danish national calendar, according to reports – a substantial departure that would place the US at odds with a large portion of the global community with no evidence for improved outcomes. The announcement has been pushed back until the coming year.

Instead of the top vaccines chief, Dr. Høeg is set to address the audience at the event. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this calendar year.

Consolidating Power at the FDA

This interim role may indicate a closer partnership between the drug and vaccine branches as Høeg and Dr. Prasad solidify control at the agency – and it signals a renewed priority upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for ending specific childhood immunization guidelines in the US to become more similar to the Danish model, a country with nationalized medicine and a number of inhabitants roughly the population of Wisconsin’s.

So far comments, she has kept her attention on immunizations – traditionally the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Expertise

Dr. Høeg has no obvious track record in pharmaceutical research, oversight or management, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and CBER since spring.

“She doesn’t seem to have the necessary background” for leading the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a scientific study. She is not versed in running a major agency. She lacks background in drug approvals.”

Previous heads of CBER would “be deeply familiar with regulatory frameworks and the research of medication creation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the type of experience that prior appointees who ran the center have had.”

CDER has an immense workload at the agency, the former commissioner stated.

“The public just focuses on the new drug program, but the generic drug division clears thousands of generic drugs. There’s a biosimilars program, non-prescription drug unit and other areas, and all of those must be managed,” Dr. Woodcock noted. “The responsibility you neglect, that’s the thing that I always told people is going to bite you.”

There is also, a significant administrative component to the job, which supervises more than 5,000 employees. “It’s a massive leadership role, if you perform it correctly,” the former official concluded.

Official Statement and Contentious Policies

When asked about questions about Dr. Høeg's credentials and whether this assignment indicates increased cooperation among regulatory chiefs on vaccines, a spokesperson responded that the “concerns are based on incorrect premises”.

“Her experience matches the duties of her role,” the official explained, noting the time Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg takes over the commissioner’s recently launched expedited review system, a contentious one-day medication authorization process that allegedly worried her predecessors. “How are these medications being selected for this voucher program? Who takes the choices?” Howard questioned. “There is a lot of secrecy occurring at the agency right now.”

Overall, he remarked, “the agency appears to be shifting towards laxer oversight of all drugs, except for immunizations.”

Public Past Work on Immunizations

Concerning vaccines, Høeg has a clearer, if concerning, past, some experts have noted. She authored a study using non-validated volunteer-provided data to determine the rate of heart inflammation after COVID-19 immunization. She counseled the Florida top health official Dr. Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccines are more dangerous than they are.

Included in her “desired changes” for the current federal leadership included revising regulations for new vaccines and discontinuing “optional” vaccines, she remarked following the vote on a audio program. At the agency, Dr. Høeg has allegedly floated the idea of preventing adolescent males from obtaining COVID-19 vaccines.

“She’s an complete ideologue who commences with her preconceived notions and reverse-engineers to retrofit the evidence in a highly disingenuous, dishonest manner,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Høeg aligned with other contrarians, {like|